Degenerative Sacroiliitis held the dominant position in the sacroiliac joint fusion market in 2025, accounting for a 40.92% share. Its leadership is underpinned by the consistent clinical burden of age-related sacroiliac joint degeneration, which creates a steady pool of patients with persistent lower back and pelvic pain that may progress to interventional care. In the sacroiliac joint fusion market, this indication remains prominent because degenerative cases are more routinely identified in long-duration pain management pathways and are more commonly associated with patients who ultimately require procedural stabilization when conservative treatment proves insufficient.

Trauma is emerging as the fastest-growing indication in the sacroiliac joint fusion market as treatment pathways increasingly focus on restoring pelvic stability and reducing prolonged functional impairment after injury. Growth in this segment is reinforced through the practical need for timely intervention in structurally compromised joints, where traumatic damage can create clearer procedural demand than more gradual chronic conditions. Compared with other indications, trauma is gaining momentum because the clinical rationale for fusion is often more immediate, which supports faster adoption within interventional and surgical decision-making.

Treatment Type Segment Analysis: Surgery (Largest Segment) vs RF Ablation (Fastest-Growing Segment)

By 2025, Surgery held the largest share in the sacroiliac joint fusion market. This leadership reflects its established role in treating patients with persistent sacroiliac joint dysfunction when stabilization is required as part of definitive care. The segment remains ahead because surgery directly addresses joint instability and structural pain sources, making it the standard procedural route for cases where conservative approaches no longer provide adequate relief and long-term mechanical support becomes the central treatment objective.

RF Ablation is the fastest-growing treatment type in the sacroiliac joint fusion market, encouraged by rising demand for less invasive pain-focused interventions before or alongside more extensive procedural options. Its momentum comes from practical use in patients seeking symptom relief with reduced procedural burden, especially where clinicians aim to manage pain without immediately moving to operative fusion. Relative to alternatives, RF Ablation is seeing wider adoption because it fits well within stepwise treatment pathways and aligns with the need for interventions that can be delivered with less disruption while still addressing sacroiliac joint pain.